Strides Pharma Science rose 1.28% to Rs 416.60 after its Singapore-based subsidiary, Strides Pharma Global, received US FDA approval for butalbital, acetaminophen, caffeine, and codeine phosphate capsules.
The capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache.
The product is a generic version of Fioricet with Codeine Capsules of Teva Branded Pharmaceutical Product R&D, Inc.
According to IQVIA MAT May 2020 data, the US market for butalbital, acetaminophen, caffeine, and codeine phosphate capsules, 50 mg/325 mg/40 mg/30 mg, is approximately US$ 10 million. The product will be marketed by Strides Pharma Inc. in the US market, the company said in a BSE filing made before market hours today (9 July 2020).
The company has 124 cumulative abbreviated new drug application (ANDA) filings with United States Food & Drug Administration (USFDA), of which 87 ANDAs have been approved and 37 are pending approval.
Strides Pharma Science is a global pharmaceutical company. It focuses on difficult to manufacture products that are sold in over 100 countries.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app